Crossmark

Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions

Crossref DOI link: https://doi.org/10.1007/s11154-025-09958-5

Published Online: 2025-04-02

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ruggeri, Rosaria M. https://orcid.org/0000-0001-8899-684X
Grossrubatscher, Erika Maria https://orcid.org/0000-0001-7234-7618
Ciocca, Eleonora https://orcid.org/0009-0007-6554-3443
Hasballa, Iderina https://orcid.org/0009-0003-7363-571X
Jaafar, Simona https://orcid.org/0009-0002-6045-2992
Oldani, Monica https://orcid.org/0000-0002-1512-8926
Rubino, Manila https://orcid.org/0000-0002-2094-9438
Russo, Flaminia https://orcid.org/0000-0003-4703-4358
Isidori, Andrea M. https://orcid.org/0000-0002-9037-5417
Colao, Annamaria https://orcid.org/0000-0003-4049-2559
Faggiano, Antongiulio https://orcid.org/0000-0002-9324-3946
,
License Information

Text and Data Mining valid from 2025-04-02

Version of Record valid from 2025-04-02
More Information

Article History

Accepted: 17 March 2025

First Online: 2 April 2025

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: The authors declare no competing interests.